COR

Business Context and Reporting Period

This summary covers the Form 10-Q filed by AmerisourceBergen Corporation (Note: The company name in the metadata "Cencora" is incorrect for this 2006 filing; the registrant is AmerisourceBergen). The report covers the quarterly period ended December 31, 2006. The Company operates as a pharmaceutical services provider with two primary reportable segments: Pharmaceutical Distribution (including AmerisourceBergen Drug Corporation, Specialty Group, and Packaging Group) and PharMerica (Long-Term Care and workers' compensation services).

Key Financial Metrics

Margins: Gross profit margin was 3.79% of operating revenue (down 11 basis points from 3.90% prior year). Operating income margin was 1.33% (up 10 basis points from 1.23%).

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 16% year-over-year, driven by 11% growth in the AmerisourceBergen Drug Corporation (ABDC) segment and 40% growth in the Specialty Group (ABSG). Acquisitions contributed approximately 1.5% to revenue growth.
• Profitability: Net income rose 26% and diluted EPS increased 37%. The EPS increase was amplified by share repurchases reducing the weighted average shares outstanding.
• Antitrust Gains: Gains from antitrust litigation settlements dropped significantly to $1.9 million in Q4 2006 from $18.0 million in Q4 2005. These gains are recorded as reductions to cost of goods sold.
• Acquisitions: The Company spent $143.5 million on acquisitions in the quarter, including Health Advocates ($83.5M), I.G.G. of America ($36.9M), and Access M.D. ($12.5M).
• Share Repurchases: The Company repurchased 7.2 million shares for $325.6 million, compared to 2.3 million shares for $88.9 million in the prior year.

Guidance, Outlook, and Risks

• Revenue Outlook: Management expects the 16% operating revenue growth rate to moderate to a range of 9% to 11% for the fiscal year ending September 30, 2007. This moderation is due to the non-renewal of a large, low-margin customer contract (approx. $1.0B revenue) effective February 2007 and the anniversary of prior-year Canadian acquisitions.
• PharMerica Spin-off: The Company signed an agreement to combine its PharMerica Long-Term Care business with Kindred Healthcare's pharmacy business into a new independent public company. The transaction is expected to close in Q2 2007 and is intended to be tax-free.
• Regulatory Risks: Significant risks include the Deficit Reduction Act (DRA) of 2005, which may reduce Medicaid reimbursement rates for generic drugs starting in 2007. Additionally, new federal and state regulations regarding prescription drug pedigrees and track-and-trace technologies (e.g., RFID in California) may increase operational costs.
• Legal Contingencies: A former executive litigation (Bergen Brunswig Matter) resulted in a court award of $19.4 million (net of prior payments), of which $13.9 million was recorded in fiscal 2006. Both parties have appealed the ruling.
• Capital Allocation: The Company expects fiscal 2007 operating cash flow between $525 million and $625 million. Capital expenditures are estimated at $100 million to $125 million for the fiscal year.

Investor Verification Checklist

• Customer Concentration: Verify the impact of the non-renewal of the large, low-margin customer contract effective February 2007 on future revenue guidance.
• PharMerica Transaction: Monitor the closing status of the PharMerica/Kindred spin-off and the associated one-time cash distribution expected from the new entity.
• Reimbursement Rates: Assess the financial impact of the Deficit Reduction Act (DRA) and new CMS rules on the Long-Term Care segment's profitability in 2007.
• Antitrust Volatility: Note that gross profit margins are currently supported by antitrust litigation settlements; verify if future quarters will sustain margins without these non-recurring gains.
• Debt Structure: Review the new $750 million Multi-Currency Revolving Credit Facility entered in November 2006 and its impact on interest expense and financial flexibility.